The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Review of drug interactions with telaprevir and antiretrovirals
van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Antivir Ther. 2013 Jan 23. doi: 10.3851/IMP2527. [Epub ahead of print]
Source
Janssen Infectious Diseases BVBA, Beerse, Belgium. rvheesw1@its.jnj.com.
Abstract
Hepatitis C Virus (HCV) infection is a major cause of mortality worldwide. HCV-related deaths also represent a leading cause of mortality in HIV co-infected individuals. Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic HCV genotype 1 infection in adults in combination with pegylated interferon and ribavirin. Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype 1 mono-infected patients, and studies in HCV/HIV co-infected patients are ongoing. Drug-drug interactions of telaprevir with antiretroviral drugs were investigated in a series of studies in healthy subjects. This review summarises the results of interaction studies with low-dose ritonavir, ritonavir-boosted HIV protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir), efavirenz, etravirine, rilpivirine, tenofovir disoproxil fumarate, and raltegravir.